Comparison of IVF-ET Outcomes between GnRH Antagonist Multiple Dose Protocol and GnRH Agonist Long Protocol in Patients with High Basal FSH Level or Advanced Age
![]() |
Kim, JY
(Department of Obstetrics and Gynecology, Pochon CHA University, College of Medicine)
Kim, NK (Department of Obstetrics and Gynecology, Pochon CHA University, College of Medicine) Yoon, TK (Department of Obstetrics and Gynecology, Pochon CHA University, College of Medicine) Cha, SH (Department of Obstetrics and Gynecology, Pochon CHA University, College of Medicine) Kim, YS (Department of Obstetrics and Gynecology, Pochon CHA University, College of Medicine) Won, HJ (Department of Obstetrics and Gynecology, Pochon CHA University, College of Medicine) Cho, JH (Department of Obstetrics and Gynecology, Pochon CHA University, College of Medicine) Cha, SK (Fertility Center of CHA General Hospital) Chung, MK (Fertility Center of CHA General Hospital) Choi, DH (Department of Obstetrics and Gynecology, Pochon CHA University, College of Medicine) |
1 | Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum Reprod 2000; 15: 2145-7 DOI ScienceOn |
2 | Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 2003; 9: 61-76 DOI ScienceOn |
3 | Erenus M, Souves C, Raj amahendr an P, Leung S, Fluker M, Gomel V. The effect of embryo quality on subsequent pregnancy rates after in vitro fertilization. Fertil Steril 1991; 56: 707-10 DOI |
4 | Hugues JN, Cedrin DI. Revisiting gonadotrophinreleasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum Reprod 1998; 4: 83-101 |
5 | Fluker MR. Gonadotropin-releasing hormone antagonists. Curr Opin Endocrinol Diabetes 2000; 7: 350-6 DOI ScienceOn |
6 | Albano C, Felberbaum RE, Smitz J, RiethmullerWinzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH) antagonist ceterorelix and the LHRH-agonist buserelin. Hum Reprod 2000; 15: 526-31 DOI ScienceOn |
7 | Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilizationembryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314-20 DOI PUBMED ScienceOn |
8 | Garcia JE, Jones GS, Acosta AA, Wright G. HMG/HCG follicular maturation for oocytes aspiration: phase 11,1981. Fertil Steril 1983; 39: 174-9 DOI |
9 | 이은실, 김동환, 배도환. 저반응군 환자에서 GnRH Antagonist를 이용한 과배란 유도의 효용성에 관한 연구. 대한산부회지 2003; 46: 1999-2004 |
10 | Borm G, Mannaerts B. The European Orgalutran Study Group. Treatment with the gonadotropinreleasing hormone antagonist Ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulation hormone is effective, safe and convenient: results of a controlled, randomized multicenter trial. Hum Reprod 2000; 15: 1490-8 DOI ScienceOn |
11 | Fasouliotis SJ, Simon A, Laufer N. Evaluation and treatment of low responders in assisted reproductive technology: A challenge to meet. J Assist Reprod Genet 2000; 17: 357-73 DOI ScienceOn |
12 | Fleming R, Adam AH, Barlow DH, Black WP, MacNaughton MC, Coutts JR. A new systemic treatment for infertile women with abnormal hormone profiles. Br J Obstet Gynecol 1982; 89: 80-3 DOI |
13 | 김정훈, 조윤경, 목정은. 난소 기능 예측인자로서 Immunoradiometric Assay로 측정 된 기초 혈중 난포자극호르몬 농도의 임상적 유용성에 관한 연구. 대한산부회지 1995; 38: 1924-36 |
14 | Loumaye E. The control of endogenous secretion of LH by gonadotropin-releasing hormone agonists during ovarian hyperstimulation for in vitro fertilization and embryo transfer. Hum Reprod 1990; 5: 357-76 DOI |
15 | Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-upprotocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001; 16: 868-70 DOI ScienceOn |
16 | 이방현, 김정훈, 오영미. 체외수정시술을 위한 과배란 유도에 있어 GnRH Antagonist 다회 투여법과 GnRH Agonist 장기요법의 비교 연구. 대한산부회지 2003; 46: 1202-8 |
17 | Scott RT, Hoffnab GE, Oehninger S, Muasher SJ. Intercycle variability of day 3 follicle stimulating hormone levels and its effect on stimulation quality in vitro fertilization. Fertil Steril 1990; 53: 297 |
18 | Van Rooij IA, Bancsi LF, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Women older than 40 years of age and those with elevated folliclestimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization. Fertil Steril 2003; 79(3): 482-8 DOI ScienceOn |
19 | Olivennes F, Kadhel P, Rufat P, Fanchin R, Fernandez H, Frydman R. Perinatal outcome of twin pregnancies obtained after in vitro fertilization: comparison with twin pregnancies obtained spontaneously or after ovarian stimulation. Fertil Steril 1996; 66: 105-9 DOI |
20 | 김문영, 정병준. GnRH Antagonist (Cetrotide) Short Protocol의 임상적 유용성에 관한 연구. 대한산부회지 2001; 28: 265-70 과학기술학회마을 |
21 | Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tier CC, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randommized controlled trial. Hum Reprod 2005; 20: 616-21 DOI ScienceOn |
22 | Ben-Rafael Z, Lipitz S, Bider D, Maschiach S. Ovarian hyporesponsiveness in combined gonadotropinreleasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril 1991; 55: 272-5 DOI |
![]() |